drugset / Trial / NCT00303550

Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)

NCT00303550 ↗

Phase 3 Completed Arpida AG
RandomizedParallel-groupDouble-blindTreatment

Summary

The study is now completed

Timeline

Start
2006-03
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Linezolid Other / unclassified — Intravenous
Subject iclaprim Small molecule — Intravenous